


Product Name : DCC-2618
Cat. No. : PC-62101
CAS No. : 1442472-39-0
Molecular Formula : C₂₄H₂₁BrFN₅O₂
Molecular Weight : 510.367
Target : c-Kit
Solubility : 10 mM in DMSO



Biological Activity

DCC-2618 (Ripretinib, DCC2618) is a potent, oral inhibitor of singly and doubly mutated **KIT** with IC₅₀ of WT (IC₅₀=4 nM), V654A (8 nM), T670I (18 nM), D816H (5 nM), D816V.

DCC-2618 also inhibits PDGFRα/β, KDR and cFMS, robustly inhibits exon 17, exon 9/13, exon 9/14, and exon 9/17 KIT mutants, as well as exon 11/17 KIT mutants.

DCC-2618 inhibits wild type and mutant KIT phosphorylation in cancer cells, demonstrates the potential to treat KIT mutant-driven cancers including GIST, systemic mastocytosis, AML, or melanoma.

References

Mathias A Schneeweiss, et al. *Blood* 2016 128:1965.

Cancer Discov. 2017 Feb;7(2):121-122. doi: 10.1158/2159-8290.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com